MX2020008702A - Metodos para la deteccion y tratamiento del cancer de prostata. - Google Patents

Metodos para la deteccion y tratamiento del cancer de prostata.

Info

Publication number
MX2020008702A
MX2020008702A MX2020008702A MX2020008702A MX2020008702A MX 2020008702 A MX2020008702 A MX 2020008702A MX 2020008702 A MX2020008702 A MX 2020008702A MX 2020008702 A MX2020008702 A MX 2020008702A MX 2020008702 A MX2020008702 A MX 2020008702A
Authority
MX
Mexico
Prior art keywords
methods
prostate cancer
treatment
cancer detection
prostate
Prior art date
Application number
MX2020008702A
Other languages
English (en)
Spanish (es)
Inventor
Mark Kidd
Irvin Mark Modlin
Ignat Drozdov
Original Assignee
Liquid Biopsy Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liquid Biopsy Res Llc filed Critical Liquid Biopsy Res Llc
Publication of MX2020008702A publication Critical patent/MX2020008702A/es

Links

Classifications

    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • GPHYSICS
    • G16INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16BBIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2537/00Reactions characterised by the reaction format or use of a specific feature
    • C12Q2537/10Reactions characterised by the reaction format or use of a specific feature the purpose or use of
    • C12Q2537/143Multiplexing, i.e. use of multiple primers or probes in a single reaction, usually for simultaneously analyse of multiple analysis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/112Disease subtyping, staging or classification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Theoretical Computer Science (AREA)
  • Artificial Intelligence (AREA)
  • Bioethics (AREA)
  • Computer Vision & Pattern Recognition (AREA)
  • Data Mining & Analysis (AREA)
  • Databases & Information Systems (AREA)
  • Epidemiology (AREA)
  • Evolutionary Computation (AREA)
  • Public Health (AREA)
  • Software Systems (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MX2020008702A 2018-02-22 2019-02-21 Metodos para la deteccion y tratamiento del cancer de prostata. MX2020008702A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862633675P 2018-02-22 2018-02-22
PCT/US2019/018878 WO2019165021A1 (en) 2018-02-22 2019-02-21 Methods for prostate cancer detection and treatment

Publications (1)

Publication Number Publication Date
MX2020008702A true MX2020008702A (es) 2020-09-25

Family

ID=65686083

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008702A MX2020008702A (es) 2018-02-22 2019-02-21 Metodos para la deteccion y tratamiento del cancer de prostata.
MX2025000449A MX2025000449A (es) 2018-02-22 2020-08-20 Metodos in vitro para la deteccion del cancer de prostata

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2025000449A MX2025000449A (es) 2018-02-22 2020-08-20 Metodos in vitro para la deteccion del cancer de prostata

Country Status (15)

Country Link
US (3) US11410748B2 (cg-RX-API-DMAC7.html)
EP (2) EP3755816B1 (cg-RX-API-DMAC7.html)
JP (2) JP7662337B2 (cg-RX-API-DMAC7.html)
KR (2) KR20260018206A (cg-RX-API-DMAC7.html)
CN (2) CN119932188A (cg-RX-API-DMAC7.html)
AU (2) AU2019224025B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016989A2 (cg-RX-API-DMAC7.html)
CA (1) CA3091647A1 (cg-RX-API-DMAC7.html)
DK (1) DK3755816T3 (cg-RX-API-DMAC7.html)
ES (1) ES3023842T3 (cg-RX-API-DMAC7.html)
IL (1) IL276748A (cg-RX-API-DMAC7.html)
MX (2) MX2020008702A (cg-RX-API-DMAC7.html)
PL (1) PL3755816T3 (cg-RX-API-DMAC7.html)
SG (1) SG11202007922XA (cg-RX-API-DMAC7.html)
WO (1) WO2019165021A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114901819A (zh) 2019-10-10 2022-08-12 液体活检研究有限责任公司 用于生物样品和rna稳定化的组合物、方法和试剂盒
JP7757291B2 (ja) * 2020-02-06 2025-10-21 オンコホスト リミテッド 治療法応答の機械学習予測
WO2023017525A1 (en) 2021-08-11 2023-02-16 OncoHost Ltd. Predicting patient response
JP2025534688A (ja) 2022-10-12 2025-10-17 リキッド バイオプシー リサーチ リミティド ライアビリティ カンパニー 唾液において前立腺癌を検出するための方法
GB2623570B (en) * 2022-10-21 2025-07-23 Wobble Genomics Ltd Method and products for biomarker identification
KR102891032B1 (ko) * 2022-12-29 2025-12-03 재단법인대구경북과학기술원 혈액 단구세포 전사체 생체표지자를 이용한 전이성 전립선암 진단용 바이오마커 및 이의 용도
CN116908444B (zh) * 2023-09-13 2023-12-19 中国医学科学院北京协和医院 血浆max自身抗体在晚期非小细胞肺癌pd-1单抗联合化疗治疗预后预测中的应用
CN119964650B (zh) * 2024-12-24 2025-09-30 深圳大学 一种基于集成学习的基因调控网络推断方法和系统

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007271232A1 (en) * 2006-07-03 2008-01-10 Exonhit Therapeutics Sa Prostate specific transcripts and the use thereof for prostate cancer therapeutics and diagnostics
US20100303795A1 (en) * 2009-05-27 2010-12-02 Soerensen Karina Dalsgaard Marker of prostate cancer
IL243203A (en) * 2010-07-27 2017-04-30 Genomic Health Inc Method for using gene expression to determine prognosis of prostate cancer
DK3179393T3 (da) * 2012-01-31 2020-07-27 Genomic Health Inc Genexpressionsprofilalgoritme og -test til bestemmelse af prognosen for prostatakræft
HK1210230A1 (en) * 2012-07-20 2016-04-15 戴格努生命科学公司 Methods, kits and compositions for providing a clinical assessment of prostate cancer
US10081842B2 (en) * 2012-08-07 2018-09-25 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Prostate cancer gene expression profiles
KR20150110477A (ko) * 2012-11-20 2015-10-02 파디아 에이비 공격적인 전립선 암의 존재 또는 부존재를 나타내는 방법
PL2945628T3 (pl) * 2013-01-15 2020-09-21 Aragon Pharmaceuticals, Inc. Modulator receptorów androgenowych w skojarzeniu z octanem abirateronu i prednizonem do leczenia nowotworu stercza
JP2016521966A (ja) * 2013-03-15 2016-07-28 メタマーク ジェネティクス, インコーポレイテッド 癌の予後のための組成物および方法
US20160130661A1 (en) * 2013-06-13 2016-05-12 University Of South Australia Methods for detecting prostate cancer
CA2920429C (en) 2013-08-06 2021-11-16 Exosome Diagnostics, Inc. Urine biomarker cohorts, gene expression signatures, and methods of use thereof
EP3214444A1 (en) * 2016-03-04 2017-09-06 AIT Austrian Institute of Technology GmbH Prostate cancer diagnostic method and means

Also Published As

Publication number Publication date
ES3023842T3 (en) 2025-06-03
SG11202007922XA (en) 2020-09-29
AU2019224025A1 (en) 2020-09-10
EP3755816A1 (en) 2020-12-30
US20260066046A1 (en) 2026-03-05
US20230298695A1 (en) 2023-09-21
US20190259471A1 (en) 2019-08-22
JP2021514624A (ja) 2021-06-17
AU2025238057A1 (en) 2025-11-27
CN112673115B (zh) 2025-02-18
KR102921718B1 (ko) 2026-02-03
KR20260018206A (ko) 2026-02-06
AU2019224025B2 (en) 2025-06-26
IL276748A (en) 2020-10-29
EP3755816B1 (en) 2025-02-12
WO2019165021A1 (en) 2019-08-29
CN112673115A (zh) 2021-04-16
KR20200123450A (ko) 2020-10-29
CN119932188A (zh) 2025-05-06
BR112020016989A2 (pt) 2020-12-29
DK3755816T3 (da) 2025-04-28
CA3091647A1 (en) 2019-08-29
JP2025096376A (ja) 2025-06-26
EP4538393A3 (en) 2025-07-02
JP7662337B2 (ja) 2025-04-15
MX2025000449A (es) 2025-03-07
US11410748B2 (en) 2022-08-09
PL3755816T3 (pl) 2025-06-30
EP4538393A2 (en) 2025-04-16

Similar Documents

Publication Publication Date Title
MX2020008702A (es) Metodos para la deteccion y tratamiento del cancer de prostata.
MX2023006766A (es) Composiciones que comprenden inhibidores de shp2 y metodos para tratar el cancer.
PH12021552497A1 (en) Enzyme inhibitors
PH12018500322A1 (en) Methods of treating cancer patients with farnesyltransferase inhibitors
MX2020002553A (es) Metodos de diagnostico y terapeuticos para el cancer.
EA201890957A1 (ru) Комбинированная терапия для лечения злокачественных опухолей
WO2017214373A8 (en) Diagnostic and therapeutic methods for cancer
EP3618914A4 (en) IMPLANTABLE DEVICES AND METHODS FOR TREATMENT OF BENIGNER PROSTATE HYPERPLASIA (BPH) AND RELATED LOWER URINE TRAIN SYMPTOMS (LUTS)
JOP20190272A1 (ar) مثبطات kras g12c وطرق لاستخدامها
BR112018007671A2 (pt) terapia de combinação para tratamento de malignidades
BR112022017508A2 (pt) Inibidores de egfr, kras, braf e outros alvos e uso dos mesmos
MX2020001156A (es) Metodo para el pronostico y tratamiento de metastasis de cancer.
MX2021002071A (es) Metodos relacionados con la gravedad y progresion de la lesion premaligna bronquial.
MX2024001734A (es) Metodo de modificacion de diferenciacion e inmunidad de macrofagos.
BR112015008255A2 (pt) método para o diagnóstico, prognóstico e tratamento de metástase de câncer de próstata
CL2019002438A1 (es) Uso de biomarcadores en la identificación de pacientes con cáncer que serán sensibles al tratamiento con un inhibidor de prmt5.
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
EA201890968A1 (ru) Комбинированная терапия для лечения злокачественных новообразований
WO2021162981A3 (en) Methods and compositions for identifying castration resistant neuroendocrine prostate cancer
EA201991091A1 (ru) Способы лечения пациентов со злокачественными новообразованиями с применением ингибиторов фарнезилтрансферазы
BR112021020525A2 (pt) Agente terapêutico para câncer urológico que se caracteriza por ser administrado com inibidor de il-6 e inibidor de ccr2 em combinação
MX2024006934A (es) Tratamiento del cancer con un inhibidor de la cinasa fgfr
PH12019501918A1 (en) Methods of treating cancer with farnesyltransferase inhibitors
EP3648741A4 (en) TREATMENT OF HYPERPLASTIC TISSUE GROWTH INCLUDING BENEFIT PROSTATE HYPERPLASIA (BPH) BY DIRECT INJECTION OF ANTINEOPLASTIC AGENT
EA201891693A1 (ru) Способ прогнозирования результата лечения афлиберцептом пациента, предположительно страдающего от рака, посредством измерения уровня биомаркера в плазме крови